Please login to the form below

Not currently logged in

Raffi Asadorian joins AcelRx Pharmaceuticals

He moves from biotech firm Amyris to take up chief financial officer role

Raffi AsadorianSpeciality pharmaceutical company AcelRx Pharmaceuticals has appointed Raffi Asadorian as its new chief financial officer.

He has over 25 years’ experience in finance, strategy and corporate development and was most recently chief financial officer at commercial-stage biotech company Amyris.

Asadorian said: “This is an exciting time to join AcelRx, especially with multiple upcoming milestones in the US and EU that have the potential to transform the company.

“It’s clear that the company has an experienced management team and a robust portfolio of late stage assets. I look forward to contributing to this dynamic organisation and its growth.”

Prior to joining Amyris, Asadorian was the CFO for Asa, a private equity-owned medical diagnostics company where he led finance, corporate development and investor relations.

He has also held roles at PircewaterhouseCoopers and Barr, which was later acquired by Teva Pharmaceuticals.

Vince Angotti, chief executive officer at AcelRx, said: “I am thrilled to have Raffi join our team. He is an accomplished financial executive who has held leadership roles in large multinational, specialty pharmaceutical and life sciences companies.”

1st August 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company

With a network of more than 27,000 employees conducting business in approximately 100 countries, we have helped develop or commercialize...

Latest intelligence

Waking the sleeping giant
The lights are coming on for healthcare delivery in Africa...
How to get rep buy-in for multi-channel
How do you manage a team who may be resistant to change?...
Blog: Digital therapeutics: within our reach?
Digital therapeutics is a hot topic right now. By using digital technology to manage, treat or even prevent chronic conditions, digital therapeutics is promising to revolutionise healthcare. But is this...